Lintuzumab
drugOn this page
Also known as HUM-195HUM195SGN-33Zamyl
Summary
Lintuzumab (CHEMBL2109150) is a phase-3 clinical-stage antibody targeting CD33; indicated across 7 conditions including leukemia and myelodysplastic syndrome.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (CD33)
- Indications: 7 conditions
- Clinical trials: 12
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2109150 |
| Name | Lintuzumab |
| Type | Antibody |
| Max phase | 3 |
Also known as: HUM-195, HUM195, Lintuzumab, SGN-33, Zamyl, LINTUZUMAB
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| CD33 | CD33 | Binding | 10 | 0% | P20138 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): CD33.
Top Reactome pathways
6 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Adaptive Immune System | 1 | CD33 |
| Innate Immune System | 1 | CD33 |
| Immune System | 1 | CD33 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | 1 | CD33 |
| Neutrophil degranulation | 1 | CD33 |
| Dengue Virus Attachment and Entry | 1 | CD33 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| immune response-inhibiting signal transduction | 1 |
| cell adhesion | 1 |
| signal transduction | 1 |
| cell-cell signaling | 1 |
| negative regulation of cell population proliferation | 1 |
| negative regulation of interleukin-1 beta production | 1 |
| negative regulation of interleukin-8 production | 1 |
| negative regulation of tumor necrosis factor production | 1 |
| Fc-gamma receptor signaling pathway | 1 |
| positive regulation of protein secretion | 1 |
| cell-cell adhesion | 1 |
| negative regulation of monocyte activation | 1 |
Indications & clinical
Indications
7 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| leukemia | 3 | MONDO:0005059 | EFO:0000565 |
| myelodysplastic syndrome | 2 | MONDO:0018881 | EFO:0000198 |
| acute myeloid leukemia | 2 | MONDO:0018874 | EFO:0000222 |
| neutropenia | 2 | MONDO:0001475 | MONDO:0001475 |
| plasma cell myeloma | 1 | MONDO:0009693 | EFO:0001378 |
| chronic myelomonocytic leukemia | 1 | MONDO:0020311 | EFO:1001779 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 12.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| PHASE1 | 4 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00006045 | PHASE3 | UNKNOWN | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia |
| NCT00002609 | PHASE2 | COMPLETED | Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission |
| NCT00002800 | PHASE2 | COMPLETED | Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome |
| NCT00003984 | PHASE2 | WITHDRAWN | Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome |
| NCT00006084 | PHASE2 | UNKNOWN | Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia |
| NCT00016159 | PHASE2 | COMPLETED | Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia |
| NCT00528333 | PHASE2 | COMPLETED | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML |
| NCT00997243 | PHASE2 | TERMINATED | Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes |
| NCT00002890 | PHASE1 | COMPLETED | Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous Leukemia |
| NCT00038051 | PHASE1 | COMPLETED | Evaluation of the Anti-CD-33 Immunotoxin Hum-195/rGel in Patients With Advanced Myeloid Malignancies |
| NCT00283114 | PHASE1 | COMPLETED | A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome |
| NCT00502112 | PHASE1 | COMPLETED | A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).